| Literature DB >> 34193300 |
Yangmin Hu1, Danyang Li2, Lingcheng Xu1, Yuping Hu3, Yiwen Sang4, Gensheng Zhang2, Haibin Dai5.
Abstract
BACKGROUND: Infection is the leading cause of morbidity and mortality among burn patients, and bloodstream infection (BSI) is the most serious. This study aimed to evaluate the epidemiology and clinical outcomes of BSI in severe burn patients.Entities:
Keywords: Bloodstream infection; Burns; Mortality; Multidrug resistance
Mesh:
Year: 2021 PMID: 34193300 PMCID: PMC8243830 DOI: 10.1186/s13756-021-00969-w
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Risk factors for BSI of the patients with burns over 20% TBSA
| Characteristic, n (%) | Total (n = 495) | Non-BSI (n = 359) | BSI (n = 136) | Univariate analysis | Multivariate logistic regression analysis | |
|---|---|---|---|---|---|---|
| OR (95% CI) | ||||||
| Male | 371 (74.9) | 271 (75.5) | 100 (73.5) | 0.654 | – | – |
| Age (median, IQR) | 46 [36,56] | 46 [35,56] | 47 [37,56] | 0.728 | – | – |
| Comorbidities | 121 (24.4) | 87 (24.2) | 34 (25.0) | 0.859 | – | – |
| Type of burn | ||||||
| Flame | 399 (80.6) | 283 (78.8) | 116 (85.3) | 0.104 | – | – |
| Chemical | 26 (5.3) | 21 (5.8) | 5 (3.7) | 0.333 | – | – |
| Hyperthermia liquid | 49 (9.9) | 37 (10.3) | 12 (8.8) | 0.622 | – | – |
| Other | 21 (4.2) | 18 (5.0) | 3 (2.2) | 0.166 | – | – |
| %TBSA | 0.023 | |||||
| 20–39 | 212 (42.8) | 185 (51.5) | 27 (19.9) | ˂0.001 | – | – |
| 40–59 | 130 (26.3) | 98 (27.3) | 32 (23.5) | 1.08 (0.55–2.09) | 0.828 | |
| 60–79 | 64 (12.9) | 31 (8.6) | 33 (24.3) | 2.53 (1.21–5.28) | 0.014 | |
| ≥ 80 | 89 (18.0) | 45 (12.5) | 44 (32.4) | 2.24 (1.01–4.97) | 0.048 | |
| Accompanying third degree burns | 438 (88.5) | 312 (86.9) | 126 (92.6) | 0.078 | 0.70 (0.29–1.69) | 0.423 |
| Inhalation injury | 212 (42.8) | 132 (36.8) | 80 (58.8) | ˂0.001 | 0.85 (0.51–1.44) | 0.547 |
| Mechanical ventilation | 178 (36.0) | 96 (26.7) | 82 (60.3) | ˂0.001 | 1.97 (1.12–3.47) | 0.019 |
| CVC | 352 (71.1) | 220 (61.3) | 132 (97.1) | ˂0.001 | 9.10 (3.06–27.04) | ˂0.001 |
| AKI | 56 (11.3) | 34 (9.5) | 22 (16.2) | 0.038 | 0.80 (0.38–1.67) | 0.550 |
| Hospital length of stay, days (median, IQR) | 35 [17,52] | 27 [15,44] | 50 [33,67] | ˂0.001 | 1.02 (1.01–1.03) | ˂0.001 |
BSI bloodstream infection, IQR interquartile range, TBSA total body surface area, CVC Central venous catheter, AKI acute kidney injury
Duration from admission to the first episode of BSI in burn patients
| Time after admission | Total (n = 136) | Death (n = 25) | Survival (n = 111) |
|---|---|---|---|
| 1st week | 65 (47.8) | 11 (44.0) | 54 (48.6) |
| 2nd week | 38 (27.9) | 9 (36.0) | 29 (26.1) |
| 3rd week | 19 (14.0) | 4 (16.0) | 15 (13.5) |
| ≥ 4th week | 14 (10.3) | 1 (4.0) | 13 (11.7) |
| Duration from admission to bacteremia (days) (median, IQR) | 8 [5–16] | 10 [5–13.5] | 8 [5–17] |
Causative organisms in burn patients with BSI
| Pathogens | n (n = 225) (%) |
|---|---|
| 51 (22.7) | |
| 41 (18.2) | |
| 22 (9.8) | |
| MRSA | 42 (18.7) |
| MRCNS | 23 (10.2) |
| 15 (6.7) | |
| 7 (3.1) | |
| 7 (3.1) | |
| 5 (2.2) | |
| 2 (0.9) | |
| 2 (0.9) | |
| 1 (0.4) | |
| 1 (0.4) | |
| 6 (2.7) |
MRSA methicillin-resistant Staphylococcus aureus, MRCNS methicillin-resistant Coagulase negative staphylococci
Antibiotic resistance in Gram-negative isolates of BSI
| Antibiotics | |||
|---|---|---|---|
| Amikacin | 75.0 | 52.8 | 45.0 |
| Ceftazidime | 95.0 | 88.9 | 30.0 |
| Cefepime | 95.0 | 80.6 | 65.0 |
| Ciprofloxacin | 95.0 | 86.1 | 50.0 |
| Levofloxacin | 72.5 | 80.6 | 55.0 |
| Imipenem | 95.0 | 77.8 | 75.0 |
| Meropenem | 95.0 | 77.8 | 75.0 |
| Cefoperazone-Sulbactam | 72.5 | 88.9 | 80.0 |
| Piperacillin-Tazobactam | 95.0 | 80.6 | 80.0 |
| Tigecycline | 11.4 (n = 45) | 24.0 (n = 29) | – |
| Polymyxin B | 0.0 (n = 21) | 0.0 (n = 18) | 0.0 (n = 9) |
Differences of characteristics of BSI burn patients receiving appropriate and inappropriate empirical antimicrobial therapy
| Variable | Empirical antimicrobial therapy | ||
|---|---|---|---|
| Appropriate | Inappropriate | ||
| Male | 59 (74.7) | 41 (71.9) | 0.719 |
| Age (years) (median, IQR) | 47 [34,54] | 46 [38,56] | 0.601 |
| Comorbidities | 19 (24.1) | 15 (26.3) | 0.763 |
| Type of burn | |||
| Flame | 70 (88.6) | 46 (80.7) | 0.199 |
| Chemical | 2 (2.5) | 3 (5.3) | 0.404 |
| Hyperthermia liquid | 5 (6.3) | 7 (12.3) | 0.227 |
| Other | 2 (2.5) | 1 (1.8) | 0.761 |
| %TBSA | |||
| 20–39 | 16 (20.3) | 11 (19.3) | 0.341 |
| 40–59 | 19 (24.1) | 13 (22.8) | |
| 60–79 | 23 (29.1) | 10 (17.5) | |
| ≥ 80 | 21 (26.6) | 23 (40.4) | |
| Accompanying third degree burns | 73 (92.4) | 53 (93.0) | 0.899 |
| Inhalation injury | 51 (64.6) | 29 (50.9) | 0.110 |
| Mechanical ventilation | 48 (60.8) | 34 (59.6) | 0.896 |
| Coinfections before bacteremia | |||
| Skin infection | 65 (82.3) | 37 (64.9) | 0.021 |
| Pneumonia | 38 (48.1) | 19 (33.3) | 0.085 |
| CVC infection | 24 (30.4) | 14 (24.6) | 0.456 |
| UTI | 3 (3.8) | 3 (5.3) | 0.681 |
| AKI | 9 (11.4) | 13 (22.8) | 0.074 |
| Septic shock | 9 (11.4) | 9 (15.8) | 0.455 |
| MODS | 7 (8.9) | 12 (21.1) | 0.043 |
| Hospital length of stay, days (median, IQR) | 51 [34,68] | 47 [30,66] | 0.642 |
| Inappropriate definitive antimicrobial therapy | 3 (3.8) | 13 (22.8) | 0.001 |
| Outcomes | |||
| 30-day mortality | 6 (7.6) | 10 (17.5) | 0.076 |
| 60-day mortality | 11 (13.9) | 14 (24.6) | 0.114 |
BSI bloodstream infection, IQR interquartile range, TBSA total body surface area, CVC central venous catheter, UTI urinary tract infection, AKI acute kidney injury, MODS multiple organ dysfunction syndrome
Fig. 1Kaplan–Meier curves of 30-day mortality (a) and 60-day mortality (b) according empiric therapy for BSI in burn patients
Univariate and multivariate Cox regression analyses of variables associated with 30-day mortality of BSI in burn patients
| Variable | Crude analysis | Adjusted analysis | ||
|---|---|---|---|---|
| HR (95%CI) | HR (95%CI) | |||
| Male | 0.70 (0.20–2.47) | 0.583 | ||
| Age | 1.00 (0.97–1.04) | 0.856 | ||
| Comorbidities | 0.72 (0.21–2.53) | 0.609 | ||
| Type of burn (Flame) | 0.52 (0.17–1.60) | 0.253 | ||
| ≥ 80% TBSA | 0.14 (0.05–0.44) | 0.001 | 0.86 (0.22–3.38) | 0.861 |
| Accompanying third degree burns | 22.7 (0.01,7204.37) | 0.448 | ||
| Inhalation injury | 1.55 (0.54–4.46) | 0.417 | ||
| Mechanical ventilation | 10.77 (1.42–81.54) | 0.021 | 4.14 (0.41–41.53) | 0.228 |
| Coinfections before bacteremia | ||||
| Skin infection | 0.72 (0.25–2.08) | 0.546 | ||
| Pneumonia | 1.40 (0.53–3.72) | 0.503 | ||
| CVC infection | 0.36 (0.08–1.57) | 0.171 | ||
| UTI | 1.43 (0.19–10.84) | 0.728 | ||
| AKI | 42.85 (12.10–151.78) | < 0.001 | 12.26 (2.31–64.98) | 0.003 |
| Septic shock | 36.98 (12.79–106.87) | < 0.001 | 4.36 (1.16–16.34) | 0.031 |
| Inappropriate empirical antimicrobial therapy | 0.42 (0.15–1.16) | 0.093 | 0.56 (0.17–1.89) | 0.351 |
| Inappropriate definitive antimicrobial therapy | 0.25 (0.09–0.72) | 0.010 | 0.52 (0.12–2.19) | 0.371 |
HR hazard ratio, CI confidence interval, TBSA total body surface area, CVC central venous catheter, UTI urinary tract infection, AKI acute kidney injury